Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs.

2023/06/01 by Elisa Giommoni, Serena Pillozzi, Carlotta Ottanelli +15

paper · doi:10.1200/jco.2023.41.16_suppl.e21144

Abstract

e21144 Background: Immune Checkpoint Inhibitors (ICIs) changed the algorithm of treatment for Non-Small Cell Lung Cancer (NSCLC). Consequently, an increased incidence of specific immune-related adverse events (irAEs) were reported, although a clear relationship between toxicity and response to ICIs was not identified. To date no strong predictive factor of response to ICIs are univocally recognized in NSCLC. Methods: This is an observational, retro-prospective, monocentric study aimed to evaluate, in patients (pts) with NSCLC treated with ICIs, the predictive impact of selected blood biomarkers and the occurrence of irAEs on survival. Differential cells count, and specifically the Absolute Eosinophil Count (AEC, N°/μL), were registered at baseline to evaluate their impact on response to ICIs. Patients were divided in two groups: those with high AEC ( > 190/µL, group A), and those with low basal AEC (

Related

• Association of Immune-Related Adverse Events with Efficacy in Patients With Small Cell Lung Cancer: a Second Analysis of Phase 3 IMpower133 Randomized Clinical Trials
• Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC
• Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors
• Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
• Effects of immune‐related adverse events (<scp>irAEs</scp>) and their treatment on antitumor immune responses